Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

situximab

- PMLiVE

Big opportunities in big data, but EMA and industry just getting started

250m genomes sequenced, but data trapped in silos

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

- PMLiVE

Analysts look beyond Keytruda in Merck’s future

CEO Frazier made to defend pipeline prospects

- PMLiVE

European Medicines Agency departs London ahead of Brexit

Regulator moving to Amsterdam, as Novartis adds voice to no-deal warnings

- PMLiVE

EMA says Lilly’s Lartruvo should not be prescribed

First time EMA has acted on accelerated approval follow-up

- PMLiVE

EMA sees approval numbers rise in 2018

Agency faces Brexit test in 2019

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Novartis withdraws EU filing for canakinumab

Further setback for cardiovascular blockbuster potential

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

CHMP backs Sanofi’s all-oral sleeping sickness drug

Sanofi's drug and others given green light by EMA committee

- PMLiVE

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Another setback for Roche, but CHMP changes its mind on Opdivo/Yervoy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links